Biophytis S.A. details Combined General Meeting results

Biophytis S.A. submitted a Form 6-K as a foreign private issuer to provide investors with an English-language update about its corporate governance.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

Biophytis S.A. submitted a Form 6-K as a foreign private issuer to provide investors with an English-language update about its corporate governance. The company reports that on November 13, 2025 it issued a press release announcing the results of its Combined General Meeting. That press release is included with this report as Exhibit 99.1, allowing shareholders to review the meeting outcomes in more detail.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Biophytis S.A. (BPTSY) report in this Form 6-K?

Biophytis S.A. reports that it issued a press release on November 13, 2025 announcing the results of its Combined General Meeting. The Form 6-K mainly serves to furnish that press release as Exhibit 99.1 for investors.

What is the key date mentioned in Biophytis (BPTSY) Form 6-K?

The key date is November 13, 2025, when Biophytis S.A. issued a press release on the results of its Combined General Meeting. The Form 6-K itself is dated November 14, 2025 as the report date.

What exhibit is attached to Biophytis S.A. (BPTSY) November 2025 Form 6-K?

The Form 6-K includes one exhibit, labeled 99.1, which is a press release dated November 13, 2025. That press release contains details about the results of Biophytis S.A.’s Combined General Meeting.

Why did Biophytis S.A. (BPTSY) file this Form 6-K?

Biophytis S.A. filed this Form 6-K to furnish a press release announcing the results of its Combined General Meeting. As a foreign private issuer, the company uses Form 6-K to share such material information with U.S. investors.

Which annual report form does Biophytis S.A. (BPTSY) use according to this filing?

Biophytis S.A. indicates that it files, or will file, its annual reports under cover of Form 20-F. This confirms its reporting framework as a foreign private issuer under U.S. securities regulations.

Who signed the November 2025 Biophytis S.A. (BPTSY) Form 6-K?

The Form 6-K was signed on behalf of Biophytis S.A. by Stanislas Veillet. He is identified in the document as the company’s Chairman and Chief Executive Officer at the time of signing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/14/2025 - 08:54 AM EST

UNITED STATES SECURITIES

AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: November 14, 2025

Commission File Number: 001-38974

BIOPHYTIS S.A.

(Translation of registrant’s name into English)

Stanislas Veillet
Biophytis S.A.

Sorbonne University—BC 9, Bâtiment A 4ème étage

4 place Jussieu

75005 Paris, France

+33 1 44 27 23 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

x Form 20-F ¨ Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

On November 13, 2025, Biophytis S.A. issued a press release announcing the results of the Combined General Meeting. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K.

EXHIBIT LIST

Exhibit		Description
99.1		Press Release dated November 13, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOPHYTIS S.A.

Date: November 14, 2025	By:	/s/ Stanislas Veillet
		Name: Stanislas Veillet
		Title: Chairman and Chief Executive Officer

Source: View Original Filing on SEC EDGAR